Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 194-202

  Thompson, Ruth ^a,c   Meuth, Mark ^a   Wol, Penela ^b   Zhu, Yong ^a   Danson, Sarah ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cell cycle; Checkpoint kinase 1; Chemoresistance; Cisplatin; G 6976; Small cell lung cancer

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; CASPASE 3; CHECKPOINT KINASE 1; CISPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; DNA DAMAGE; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; LUNG CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBAZOLES; CARCINOMA, SMALL CELL; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 84455174466     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1187     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, et al.: Cancer Statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Eckert F and Muller AC: SCLC extensive disease-treatment guidance by extent or/and biology of response? Radiat Oncol 3: 33, 2008.
3. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH and Reedijk J: Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification, and quantitation. Biochemistry 24: 707-713, 1985.
4. Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269: 787-790, 1994.
5. Lambert S, Mason SJ, Barber LJ, et al.: Schizosaccharomyces pombe checkpoint response to DNA interstrand cross-links. Mol Cell Biol 23: 4728-4737, 2003. (Pubitemid 36734758)
6. Niedernhofer LJ, Odijk H, Budzowska M, et al.: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787, 2004. (Pubitemid 38787963)
7. Wang J, Pabla N, Wang CY, Wang W, Schoenlein PV and Dong Z: Caspase-mediated cleavage of ATM during cisplatin-induced tubular cell apoptosis: inactivation of its kinase activity toward p53. Am J Physiol Renal Physiol 291: F1300-F1307, 2006. (Pubitemid 44887243)
8. Colton SL, Xu XS, Wang YA and Wang G: The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J Biol Chem 281: 27117-27125, 2006. (Pubitemid 44401741)
9. Shinomiya N, Takemura T, Iwamoto K and Rokutanda M: Caffeine induces S-phase apoptosis in cis-diamminedichloro-platinum-treated cells, whereas cis-diamminedichloroplatinum induces a block in G2/M. Cytometry 27: 365-373, 1997. (Pubitemid 27158398)
10. Takahashi I, Kobayashi E, Asano K, Yoshida M and Nakano H: UCN-01, a selective inhibitor of protein kinase C from streptomyces. J Antibiot (Tokyo) 40: 1782-1784, 1987. (Pubitemid 18023359)
11. Busby EC, Leistritz DF, Abraham RT, Karnitz LM and Sarkaria JN: The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 60: 2108-2112, 2000. (Pubitemid 30225168)
12. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA and O'Connor PM: UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88: 956-965, 1996. (Pubitemid 26239383)
13. Bunch RT and Eastman A: 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ 8: 779-788, 1997. (Pubitemid 27287809)
14. Mack PC, Gandara DR, Lau AH, Lara PN Jr, Edelman MJ and Gumerlock PH: Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol 51: 337-348, 2003. (Pubitemid 36629812)
15. Fuse E, Tanii H, Kurata N, et al.: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58: 3248-3253, 1998. (Pubitemid 28371060)
16. Kohn EA, Yoo CJ and Eastman A: The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res 63: 31-35, 2003. (Pubitemid 36070415)
17. Carmichael J, Mitchell JB, DeGraff WG, et al.: Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer 57: 540-547, 1988.
18. Li CH, Tzeng SL, Cheng YW and Kang JJ: Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem 280: 26193-26199, 2005. (Pubitemid 41022215)
19. Bolderson E, Scorah J, Helleday T, Smythe C and Meuth M: ATM is required for the cellular response to thymidine induced replication fork stress. Hum Mol Genet 13: 2937-2945, 2004. (Pubitemid 39585226)
20. Clarke CA and Clarke PR: DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system. Biochem J 388: 705-712, 2005. (Pubitemid 40839948)
21. Rodriguez R, Gagou ME and Meuth M: Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45. Cell Death Differ 15: 889-898, 2008. (Pubitemid 351524431)
22. Rodriguez R and Meuth M: Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 17: 402-412, 2006. (Pubitemid 43049492)
23. Meuth M: Chk1 suppressed cell death. Cell Div 5: 21, 2010.
24. Qatsha KA, Rudolph C, Marme D, Schachtele C and May WS: Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc Natl Acad Sci USA 90: 4674-4678, 1993. (Pubitemid 23148968)
25. Shechter D, Costanzo V and Gautier J: Regulation of DNA replication by ATR: signaling in response to DNA intermediates. DNA Repair (Amst) 3: 901-908, 2004. (Pubitemid 39004090)
26. Gagou ME, Zuazua-Villar P and Meuth M: Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell 21: 739-752, 2010.
27. Fujikane T, Shimizu T, Tsuji T, Ishida S, Ohsaki Y and Onodera S: Flow cytometric analysis of the kinetic effects of cisplatin on lung cancer cells. Cytometry 10: 788-789, 1989.
28. Smith ML: Mdm2 sensitizes MCF7 breast cancer cells to cisplatin or carboplatin. Breast Cancer Res Treat 58: 99-105, 1999.
29. Pabla N, Huang S, Mi QS, Daniel R and Dong Z: ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283: 6572-6583, 2008.
30. Lee SI, Brown MK and Eastman A: Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol 58: 1713-1721, 1999. (Pubitemid 29505411)
31. Sato S, Fujita N and Tsuruo T: Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21: 1727-1738, 2002. (Pubitemid 34259036)
32. Martiny-Baron G, Kazanietz MG, Mischak H, et al.: Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268: 9194-9197, 1993. (Pubitemid 23145960)
33. Eastman A, Kohn EA, Brown MK, et al.: A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 1: 1067-1078, 2002.
34. Bunch RT and Eastman A: Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2: 791-797, 1996. (Pubitemid 26168931)
35. Graves PR, Yu L, Schwarz JK, et al.: The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275: 5600-5605, 2000. (Pubitemid 30115197)
36. Behrens MM, Strasser U and Choi DW: Go 6976 is a potent inhibitor of neurotrophin-receptor intrinsic tyrosine kinase. J Neurochem 72: 919-924, 1999. (Pubitemid 29085005)
37. Grandage VL, Everington T, Linch DC and Khwaja A: Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 135: 303-316, 2006. (Pubitemid 44484837)
38. Sidi S, Sanda T, Kennedy RD, et al.: Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133: 864-877, 2008. (Pubitemid 351715394)
39. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R and Meuth M: ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 5: e1000324, 2009.
40. O'Connell MJ, Raleigh JM, Verkade HM and Nurse P: Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 16: 545-554, 1997. (Pubitemid 27067784)
41. Centurion SA, Kuo HR and Lambert WC: Damage-resistant DNA synthesis in Fanconi anemia cells treated with a DNA cross-linking agent. Exp Cell Res 260: 216-221, 2000.
42. Pichierri P and Rosselli F: The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J 23: 1178-1187, 2004. (Pubitemid 38436881)
43. Janetka JW and Ashwell S: Checkpoint kinase inhibitors: a review of the patent literature. Expert Opin Ther Pat 19: 165-197, 2009.